Tests donor CAR-T cells with olverembatinib in newly diagnosed Philadelphia-positive leukemia
Tests CAR-T cells plus olverembatinib in adults with newly diagnosed Philadelphia-positive leukemia.
Plain-language title generated from the registry record
Registry title: Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Key facts
- Where
- Suzhou, ChinaSee the site
- Phase
- Early phase 1
Where in China
- The First Affiliated Hospital of Soochow University, Jiangsu Institute of HematologySuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Soochow University
- Trial code
- NCT07074496
- Record updated
- 17 June 2026
- Original description
This is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic leukemia.Read full original descriptionShow less
An Open, Prospective, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Allogeneic Anti CD19 CAR-T Combined With a Novel Third-generation TKI Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
This is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic leukemia.
Inclusion: Male or non-pregnant, non-lactating female patients who are 18 years of age or older; Newly diagnosed Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL, as defined by the 2016-WHO criteria. Participants should not be treated with any kind of TKIs or chemotherapy; Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, and expected survival period ≥ 3 months; Organ function as indicated by the following laboratory indicators must be met:; Alanine aminotransferase (ALT) ≤ 5×upper limit of normal (ULN), aspartate aminotransferase (AST) ≤ 5×ULN; 2. Total bilirubin<2×ULN; 3. 24-hour calculated creatinine clearance>30 mL/min; 4. SpO2≥92%; 5. Cardiac ejection fraction (EF)≥40%.
Exclusion: Patients who underwent major surgery (except for minor surgery such as catheter placement or bone marrow biopsy) within 14 days before the first drug; Uncontrolled active infection; Patients who are currently suffering from active autoimmune disease or a history of autoimmune disease potentially involving the CNS; Patients who have any history of heart or vascular disease, such as hypertension (systolic blood pressure(HBP) > 140mmHg and/or diastolic blood pressure > 90mmHg); Cardiac ultrasonography indicates that pulmonary artery systolic blood pressure is >50 mmHg; or there are clinical symptoms related to pulmonary arterial hypertension; Patients who suffer from severe bleeding disorders unrelated to Ph+ ALL; Patients who have any other malignant tumors that require treatment; Patients who suffer from any condition or illness that, in the opinion of the Investigator, would compromise patient safety or interfere with the evaluation of the safety of the research drug; Active hepatitis B virus (defined as serum HBV-DNA ≥ 2000 IU/mL), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or active syphilis infection prior to enrollment. (Subjects with HBV-DNA < 2000 IU/mL can be enrolled, but should be administered antiviral drugs such as entecavir and tenofovir with relative clinical indicators monitored simultaneously during the treatment.) ; Patients who have severe hypertriglyceridemia (triglyceride ≥ 5.6mmol/L); Patients who are pregnant, planning to become pregnant or breastfeeding; Patients who may not be able to complete all study visits or procedures required by the study protocol, including follow-up visits, and/or fail to comply with all required study procedures.